Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$65.48
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | MRK Avg Daily Volume: 10,935,000
Last Update: 02/21/17 - 4:00 PM EST
Volume: 0
YTD Performance: 11.23%
Open: $0.00
Previous Close: $65.48
52 Week Range: $49.63 - $65.87
Oustanding Shares: 2,757,137,517
Market Cap: 180,289,222,237
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 8 8
Moderate Buy 1 1 0 0
Hold 3 3 6 6
Moderate Sell 1 1 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.68 1.68 1.86 1.86
Latest Dividend: 0.47
Latest Dividend Yield: 2.88%
Dividend Ex-Date: 12/13/16
Price Earnings Ratio: 33.36
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
33.36 186.80 30.60
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
5.10% 30.65% 16.87%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.50 -0.80 -0.38
Net Income -78.00 -0.80 -0.40
EPS -77.60 -0.80 -0.38
Earnings for MRK:
EBITDA 1.95B
Revenue 10.22B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $0.82 $0.85 $3.82 $4.16
Number of Analysts 5 5 8 8
High Estimate $0.89 $0.92 $3.88 $4.73
Low Estimate $0.73 $0.81 $3.77 $3.85
Prior Year $0.89 $0.93 $3.78 $3.82
Growth Rate (Year over Year) -7.64% -8.17% 1.03% 8.87%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Bruce Kamich

 | Feb 16, 2017 | 11:18 AM EST
You might want to review your holdings in the sector.

bearishMerck target cut at BMO

Feb 15, 2017 | 6:59 AM EST
Shares of MRK now seen reaching $70, according to BMO Capital. Epoch trial had disappointing results. Outperform rating.
RMPIA
By

Jim Cramer

 | Feb 9, 2017 | 6:12 AM EST
Static doesn't work in this industry. Pipelines work.
RMPIA
By

Jim Cramer

 | Feb 8, 2017 | 11:24 AM EST
Jim Cramer compares Allergan's growth to other pharma stocks.
RMPIA
By

Mark Sebastian

 | Feb 7, 2017 | 5:22 PM EST
Would get drugs to market faster and possibly more cheaply.
RMPIA
By

Mark Sebastian

 | Feb 7, 2017 | 2:48 PM EST
Getting FDA to streamline its approval process would boost drug makers.
RMPIA
By

Bret Jensen

 | Jan 30, 2017 | 10:00 AM EST
M&A, drug approvals and Trump are all on my watch list.
By

Bret Jensen

 | Jan 20, 2017 | 12:16 PM EST
The market continues to be in rally mode as everyone watches the presidential inauguration ceremonies. Biotech is not participating in the rally. Bristol Myers-Squibb (BMY) is one reason the sector is not participating, as its key oncology drug Opdivo will not pursue accelerated approval to be used in the treatment of front-line lung cancer. Shares are down some 10% on this news. Competing oncology compound Keytruda seems to have the momentum right now and has been powering Merck's (MRK) shares recently.
RMPIA
By

Doug Kass

 | Jan 19, 2017 | 4:13 PM EST
The U.S. dollar weakened. The price of crude oil rose by about two bits to $51.40. Gold fell by $8 to $1,203. I am buyer, to replace the half position I sold soon. Ag commodities: wheat down $0.08, corn up $0.02, soybean down $0.05 and oats up $0.01. Lumber was flat. For the second day in a row bonds got schmeissed iShares Barclays 20+ Yr Treas.Bond ETF (TLT) down over a beaner, again. (Good sale in fixed income last week!) The 10-year bond yield rose by 7 basis points to 2.46%. The long bond yield rose by 5 basis points. The 2s/10s expanded by 4 basis points to about 124 basis points. Municipals got hit and so did closed-end muni-bond funds. High yield was junky - but Blackstone / GSO Strategic Credit Fund (BGB) rose by a penny. Banks continue to be sold for a second day in a row -- despite much higher bond yields and lower bond prices. Crickets from financial bulls -- who seem to rationalize the large move this week and lack of correlation to bonds as a random act. Our "Trade of the Week" (short C) is now down by 5.5% or $3 since the trade was discussed in my Diary. Retail remains for sale. But my view is that a sentiment extreme is developing. Insurance stocks got whacked, including fav Hartford Financial (HIG) . Brokerages got hit, too. Goldman Sachs (GS) , put on Best Ideas List last week at $242, is down to $231. Biotech was lower, but not materially so (Celgene (CELG)Allergan (AGN) lower). Hwwever, spec biotech roiled to the downside (Intrexon (XON) , Ziopharm Oncology (ZIOP) , Acadia Pharmaceuticals (ACAD) , Aerie Pharmaceuticals (AERI) ). Autos mixed. Ford (F) up, General Motors (GM) down. Good for our

bullishMerck upgraded at Piper

Jan 12, 2017 | 7:21 AM EST
MRK was upgraded from Neutral to Overweight, Piper Jaffray said. $72 price target. Expect conditional approval for Keytruda by May.
Nice move in GPS today. The stock is up 2.7% late in the session and is holding above last...
I have read her book, 'Dare to Serve' and have seen her interviewed multiple times by Jim ...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.